摘要:
A method for quantitative evaluation of a rearrangement or targeted genetic recombination of an individual and the immunity repertoire of an individual and the uses thereof, particularly in the case of follow-up to a treatment or in the diagnosis and/or prognosis of certain pathologies. Said method comprises at least: (a) extraction of human genomic DNA from a biological sample, (b) amplification of a segment of said genomic DNA, the size thereof ranging from a few hundreds of base pairs and several quantities of ten kb by multiplex PCR in the presence of: one or several couples of primers, and polymerase DNA or a polymerase DNA mixture enabling the amplification of segments of genomic DNA, the size thereof ranging from several hundreds of base pairs and several quantities of ten kb, having a corrective effect enabling elongation to be substantially improved, said amplification also comprising a stage of initial denaturation, cycles of denaturation, hybridation and elongation and wherein the elongation stages are carried out at least during a period of 10 minutes at 68° C.-72° C.; (c) separation of the amplified DNAg fragments and (d) detection of the rearranged or recombined segments.
摘要:
The invention relates to the field comprising the diagnosis of possible immune system disorders and the analysis of immune responses. In particular, the invention relates to a method of determining the diversity of T lymphocytes in a biological sample, based on the molecular analysis of the structure of the junctions resulting from the recombination rearrangement V(D)J of element δRec-1 with an AJ gene. More specifically, the invention relates to a method of analyzing the combinatorial diversity and/or the junctional diversity of the excision circles (TREC) resulting from the rearrangement of δRec-1, in order to determine the heterogeneity of a given population of T lymphocytes.
摘要:
The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV/HERV-W.
摘要:
The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV/HERV-W.